GSK plc reported strong sales of £31.4 billion for 2024, with Specialty Medicines growing 19% despite lower Vaccine sales. Core EPS rose 10%, while total operating profit declined due to Zantac litigation charges; a £2 billion share buyback and a 16p dividend per share were announced.